Outcomes in Lower Extremity Soft Tissue Sarcoma Patients After Limb Salvage
Functional Outcomes and Health Related Quality of Life in Lower Extremity Soft Tissue Sarcoma Patients After Limb Salvage: A Prospective Study
This study aims to:
- validate the Finnish version of the Musculoskeletal Tumor Society scale and the Toronto Extremity Salvage Score lower extremity sections and to
- assess the functional ability and health-related quality of life (HRQoL) of lower extremity sarcoma patients who have undergone limb salvage surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The first purpose of this study is to validate the Finnish version of the Musculoskeletal Tumor Society scale and the Toronto Extremity Salvage Score upper extremity sections. The second purpose is to chart the functional capabilities and health-related quality of life (HRQoL) of upper extremity sarcoma patients who have undergone limb salvage surgery with local or free flaps.
Patient hospital records are retrospectively reviewed to chart the demographic and clinical data.
The recruitment of patient takes place at the outpatient clinic of Department of Oncology, Helsinki University Hospital. The study includes a cross-sectional assessment at one year follow-up with five validated questionnaires. A follow-up is conducted three years after surgery in the outpatient clinic.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Helsinki And Uusimaa
-
Helsinki, Helsinki And Uusimaa, Finland, 00029
- Cancer center, Helsinki University Hospital and University of Helsinki
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Lower extremity soft tissue sarcoma locating in between hip/gluteus to foot
- No metastasis at the time of diagnosis
- Undergone limb salvage surgery
- A minimum of 1 year follow-up
- Written consent
- Age > 18
Exclusion Criteria:
- Age <18
- No limb-salvage surgery due to sarcoma
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Validity of the lower-limb Musculoskeletal Tumor Society score and the Toronto Extremity Salvage Score
Time Frame: two to five years
|
The validity is studied
|
two to five years
|
|
Reliability of the lower-limb Musculoskeletal Tumor Society score and the Toronto Extremity Salvage Score
Time Frame: two to five years
|
The test-retest reliability is studied
|
two to five years
|
|
Health-related quality of life after limb salvage
Time Frame: two to five years
|
Assessment of health-related quality of life
|
two to five years
|
|
Assessment of the functional ability after limb salvage
Time Frame: two to five years
|
Assessment of functional ability
|
two to five years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life Questionnaire-Core 30
Time Frame: two to five years
|
Health-related quality of life assessment
|
two to five years
|
|
The 15-dimensions health-related quality of life instrument
Time Frame: two to five years
|
Health-related quality of life assessment
|
two to five years
|
|
The Musculoskeletal Tumor Society score lower extremity section
Time Frame: two to five years
|
Functional assessment of the reconstructed limb
|
two to five years
|
|
The Toronto Extremity Salvage Score lower extremity section
Time Frame: two to five years
|
Functional assessment of the reconstructed limb
|
two to five years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Carl Blomqvist, MD, PhD, Helsinki University Hospital and University of Helsinki
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 324/13/03/02/2014/2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Limb Salvage
-
NCT02372838Completed
-
NCT03107728UnknownBraces | Limb Salvage | Lower Extremity
-
NCT05547022CompletedLimb Salvage Rates With Endovascular Therapy
-
NCT03521258UnknownTrauma | Soft Tissue Injuries | Wounds | Injury | Limb Salvage
-
NCT04410042TerminatedLimb Salvage | Cancer of the Bone
-
NCT01133145UnknownOsteitis | Joint Deformities, Acquired | Limb Salvage | Bone Transplantation | Skin Transplantation
-
NCT02674906CompletedIntra Operative Bleeding, Blood Salvage
-
NCT07442110CompletedDiabetic Foot Ulcer | Wound Healing | Dietary Supplements | Wound Closure | At Home Setting | Limb Salvage | Healed Ulcer | Diabetes Mellitus, Type 1, Type 2 | Diabetes Complication
Clinical Trials on Limb salvage
-
NCT02380651Completed
-
NCT05444270RecruitingRecurrent Epithelial Ovarian Cancer
-
NCT05667636Recruiting
-
NCT00477308Completed
-
NCT03604601CompletedRecurrent Laryngeal Carcinoma
-
NCT05008900CompletedProstate Cancer | Prostatectomy
-
NCT06143605CompletedRectal Neoplasms | Neuroendocrine Tumors
-
NCT03222232CompletedIntestinal Failure | Catheter-Related Bloodstream Infection (CRBSI) Nos
-
NCT01411345Active, not recruitingProstate Cancer | Prostate Adenocarcinoma